Business Wire

Innovation and Unmet Need Drive Prescription Drug Sales to $1.18tr by 2024: New Report from Evaluate Ltd

Share

The $1.18tr forecast for the 2024 global prescription drug market reflects the role new technologies will play in addressing unmet medical needs, as strong expectations for immuno-oncology products and emerging cell and gene therapies drive growth. In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and the projected CAGR of 6.9% from 2019-2024 significantly outpaces the 2.3% CAGR seen from 2010-2018.

Growth Drivers:

  • 2018 saw 62 FDA approvals for novel drugs, an increase over the 55 approvals in 2017
  • Oncology therapies to reach $237bn in 2024, with a CAGR of 11.4%
  • Orphan Drugs will contribute an additional $109bn in sales in 2024, compared to 2018

However, as more new technologies reach the market, drug pricing pressure may continue to intensify and dampen the overall sales outlook. R&D spending is also forecast to grow more slowly from 2019-2024 than in prior years, and decrease as a proportion of overall sales – a sign of either increasing R&D efficiency, or of companies focusing on smaller indications with lower clinical development costs.

Growth Brakes:

  • $198bn in sales are at risk between 2019 and 2024, due to patent expirations
  • Anti-rheumatics sales decline as Humira, Enbrel and Remicade face competition
  • R&D as a proportion of prescription sales is forecast to decline from 21.6% in 2018 to 18% in 2024

“Scientific advancements and health technologies are converging to deliver new options for patients, while challenging traditional drug development and commercialisation models,” said report author Ryan Waters. “The question is, which companies are best poised to take advantage of the evolving pharmaceutical market?”

Top Performers:

  • Pfizer will be the leading prescription drug company in 2024, with projected sales of $51.2bn
  • Keytruda is forecast to be the top selling drug in 2024, as Humira slips in the face of biosimilars
  • Johnson & Johnson overtakes Roche to be the biggest spender on pharmaceutical R&D in 2024

Download your complimentary copy of the “EvaluatePharma® World Preview 2019, Outlook to 2024” at https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024, or visit us at Booth #2243 at the BIO International Convention, June 3-6, in Philadelphia, PA.

About Evaluate Ltd.

Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. Our EvaluatePharma® and EvaluatePharma Vision online subscription services provide a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.

Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.

Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.

Follow us on Twitter: @EvaluatePharma, @Vantageanalysis

Contact information

Media Contact:
Evaluate and Vantage
Jennifer Dinkel
+1 617-936-7783
jennifer.dinkel@evaluate.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Parimatch Makes Statement of Intent for Newly Legalised Ukraine Gambling Industry11.8.2020 15:38:00 CESTPress release

Following the signing of Bill No. 2285-d by President Volodymyr Zelenskyi to legalise the gambling industry in Ukraine, Parimatch, the international betting and technology company, has confirmed it will be bidding for the new operating licences in the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005562/en/ Parimatch Makes Statement of Intent for Newly Legalised Ukraine Gambling Industry (Graphic: Business Wire) Parimatch was founded in Ukraine in 1994 and was amongst the first bookmakers in the CIS region to transition into a digital betting platform. Today, Parimatch has expanded internationally to become a global betting and technology brand. The company now looks to build on its heritage to become the largest and most innovative operator in its home market. Commenting on today’s signing, Sergey Portnov, CEO of Parimatchsaid: “I would firstly like to congratulate President Zelenskyi for delivering on his p

Andersen Global Enhances Africa Platform With the Addition of Law Firm in Gabon11.8.2020 15:30:00 CESTPress release

Further strengthening its global platform and adding breadth to its regional footprint in Central Africa, Andersen Global announces its expansion into Gabon through a Collaboration Agreement with Libreville-based Business & Law Consulting (B & Law Consulting). The law firm, founded in 2017, is composed of more than 10 professionals who advise businesses in the areas of contract, corporate, commercial, tax, international trade, employments and general business law. “We are devoted to providing our clients with best-in-class solutions and maintain transparency and independence when handling client matters,” Managing Partner Khadidjatou Boussougou said. “Collaborating with Andersen Global is a great opportunity for us to continue to build our momentum and improve the quality of the services offered to our clients at an international level.” Andersen Global Chairman and Andersen CEO Mark Vorsatz said, “I am impressed with the level of efficiency and enthusiasm that B & Law Consulting demon

Immervision Introduces Wide-Angle Distortion Correction Algorithms with Face and Body Protection for Videos on Smartphones11.8.2020 15:00:00 CESTPress release

Immervision, the Montreal-based developer and licensor of patented, wide-angle optics and imaging technology, today announced new real-time video distortion correction algorithms making videos the same as we see with our human eyes. The algorithms are available for mobile OEMs to license now from Immervision’s exclusive distribution partner CEVA. The addition of these new algorithms to Immervision’s broad imaging processing software portfolio will enhance the differentiation OEMs can deliver in next-generation phones. In phones, the wider field of view (FOV) creates more apparent distortion. The algorithms from Immervision fix stretched bodies, curved lines, object and face proportions in real-time adjusting to the scene without any postprocessing required - all in one solution. Immervision provides different levels of correction, varied projections and real-time adaptation to the scene and supports OEMs creating a differentiated experience. “Video recording on phones is skyrocketing a

K2View Raises $28 Million to Accelerate Rapid Expansion in the DataOps Market11.8.2020 14:00:00 CESTPress release

K2View, a leading provider of real-time DataOps solutions, today announced its $28 million funding round, which will accelerate the company’s growth and expansion in the emerging DataOps market. Forestay Capital led the round along with funding from Genesis Partners. It comes on the heels of rapid growth that saw over 75 percent CAGR in revenue, with a strong first half of 2020. This investment will be used to support the company’s go-to-market strategy as it continues its expansion in markets ripe for transformation with DataOps, such as telecom, financial services, healthcare, insurance, logistics and more. “The fastest method to achieve true agility and exceptional customer experience is moving away from 30-plus years of application-driven enterprise into the data-driven enterprise. This is a critical component for digital transformation and a massive opportunity for us,” said Achi Rotem, CEO and co-founder of K2View. “As we look to the next stage of our growth, our vision is to con

ANA Therapeutics and Quotient Sciences Announce Partnership to Manufacture Niclosamide Drug Candidate as a Potential Treatment for COVID-1911.8.2020 14:00:00 CESTPress release

ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005106/en/ Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Hea

Sealed Air Invests in Advanced Recycling Company Plastic Energy11.8.2020 13:00:00 CESTPress release

Sealed Air Corporation (NYSE: SEE) has announced it has signed a collaboration agreement with Plastic Energy, an industry-leading company in advanced recycling technology. Additionally, Sealed Air has made an equity investment in Plastic Energy Global, the parent company of Plastic Energy. Plastic Energy Global was established in 2012 with the goal of creating a circular economy for plastics by diverting plastic waste away from landfills and oceans. Headquartered in London, the company has two operations in Spain and projects developing in Western Europe and Asia, with a vision for 50 new facilities over the next 10 years. "We’re excited to join forces with Plastic Energy to innovate faster and accelerate the development of new technology that eliminates waste and ensures a circular economy for plastics,” said Ted Doheny, Sealed Air President & CEO. “This collaboration will help us meet our 2025 sustainability pledge and lead the way in transforming our industry.” “We are delighted to